Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1958 1
1962 2
1963 1
1964 8
1965 10
1966 3
1967 7
1968 3
1978 2
1979 1
1980 6
1981 1
1982 4
1983 4
1984 4
1985 9
1986 6
1987 2
1988 1
1989 5
1990 1
1992 3
1993 1
1994 4
1995 1
1996 5
1997 5
1998 4
1999 5
2000 3
2001 4
2002 6
2003 4
2004 9
2005 5
2006 5
2007 5
2008 9
2009 9
2010 4
2011 11
2012 4
2013 4
2014 6
2015 8
2016 3
2017 9
2018 2
2019 12
2020 7
2021 8
2022 7
2023 4
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Results by year

Filters applied: . Clear all
Page 1
Seronegative rheumatoid arthritis: one year in review 2023.
De Stefano L, D'Onofrio B, Gandolfo S, Bozzalla Cassione E, Mauro D, Manzo A, Ciccia F, Bugatti S. De Stefano L, et al. Among authors: gandolfo s. Clin Exp Rheumatol. 2023 Mar;41(3):554-564. doi: 10.55563/clinexprheumatol/go7g26. Epub 2023 Mar 23. Clin Exp Rheumatol. 2023. PMID: 36971084 Free article. Review.
Precision medicine in Sjögren's disease.
Gandolfo S, Bombardieri M, Pers JO, Mariette X, Ciccia F. Gandolfo S, et al. Lancet Rheumatol. 2024 Sep;6(9):e636-e647. doi: 10.1016/S2665-9913(24)00039-0. Epub 2024 May 6. Lancet Rheumatol. 2024. PMID: 38723653 Review.
Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome.
Seror R, Baron G, Camus M, Cornec D, Perrodeau E, Bowman SJ, Bombardieri M, Bootsma H, Gottenberg JE, Fisher B, Hueber W, van Roon JA, Devauchelle-Pensec V, Gergely P, Mariette X, Porcher R; NECESSITY WP5 - STAR development working group; NECESSITY WP5- STAR development working group. Seror R, et al. Ann Rheum Dis. 2022 Jul;81(7):979-989. doi: 10.1136/annrheumdis-2021-222054. Epub 2022 Apr 7. Ann Rheum Dis. 2022. PMID: 35393271 Free PMC article.
CD8+ tissue-resident memory T cells are expanded in primary Sjögren's disease and can be therapeutically targeted by CD103 blockade.
Mauro D, Lin X, Pontarini E, Wehr P, Guggino G, Tang Y, Deng C, Gandolfo S, Xiao F, Rui K, Huang E, Tian J, Raimondo S, Rischmueller M, Boroky J, Downie-Doyle S, Nel H, Baz-Morelli A, Hsu A, Maraskovsky E, Barr A, Hemon P, Chatzis L, Boschetti CE, Colella G, Alessandro R, Rizzo A, Pers JO, Bombardieri M, Thomas R, Lu L, Ciccia F. Mauro D, et al. Among authors: gandolfo s. Ann Rheum Dis. 2024 Sep 30;83(10):1345-1357. doi: 10.1136/ard-2023-225069. Ann Rheum Dis. 2024. PMID: 38777379
Emerging drugs for primary Sjögren's syndrome.
Gandolfo S, De Vita S. Gandolfo S, et al. Expert Opin Emerg Drugs. 2019 Jun;24(2):121-132. doi: 10.1080/14728214.2019.1634052. Expert Opin Emerg Drugs. 2019. PMID: 31286787 Review.
The bone marrow side of axial spondyloarthritis.
Mauro D, Gandolfo S, Tirri E, Schett G, Maksymowych WP, Ciccia F. Mauro D, et al. Among authors: gandolfo s. Nat Rev Rheumatol. 2023 Aug;19(8):519-532. doi: 10.1038/s41584-023-00986-6. Epub 2023 Jul 5. Nat Rev Rheumatol. 2023. PMID: 37407716 Review.
249 results